Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
Pérez-Simón JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, García-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, Parker A, Leon A, Yong K, Sureda A, Hunter A, Sierra J, Goldstone AH, Linch DC, San Miguel JF, Mackinnon S; Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation. Pérez-Simón JA, et al. Blood. 2002 Nov 1;100(9):3121-7. doi: 10.1182/blood-2002-03-0701. Blood. 2002. PMID: 12384408 Free article.
Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation.
Kröger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A, Perez-Simon JA, San Miguel JF, Kiehl M, Fauser A, Schwerdtfeger R, Wandt H, Sayer HG, Myint H, Klingemann H, Zabelina T, Dierlamm J, Hinke A, Zander AR. Kröger N, et al. Blood. 2004 Jun 1;103(11):4056-61. doi: 10.1182/blood-2003-12-4435. Epub 2004 Feb 24. Blood. 2004. PMID: 14982868 Free article.
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas JF, Schwerdtfeger R, Kiehl M, Fauser A, Sayer HG, Leon A, Beyer J, Zabelina T, Ayuk F, San Miguel JF, Brand R, Zander AR. Kröger N, et al. Biol Blood Marrow Transplant. 2004 Oct;10(10):698-708. doi: 10.1016/j.bbmt.2004.06.002. Biol Blood Marrow Transplant. 2004. PMID: 15389436 Free article. Clinical Trial.
Long-term immune recovery of patients undergoing allogeneic stem cell transplantation: a comparison with their respective sibling donors.
Sanchez-Guijo FM, Sanchez-Abarca LI, Bueno C, Villaron E, Lopez-Holgado N, Vazquez L, Lopez-Fidalgo J, Perez-Simon JA, Caballero MD, del Cañizo MC, Orfao A, San Miguel JF. Sanchez-Guijo FM, et al. Biol Blood Marrow Transplant. 2005 May;11(5):354-61. doi: 10.1016/j.bbmt.2005.01.008. Biol Blood Marrow Transplant. 2005. PMID: 15846289 Free article. Clinical Trial.
Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
Martino R, Pérez-Simón JA, Moreno E, Queraltó JM, Caballero D, Mateos M, Sureda A, Cañizo C, Brunet S, Briones J, Vazquez L, Clopés A, San Miguel JF, Sierra J. Martino R, et al. Biol Blood Marrow Transplant. 2005 Jun;11(6):437-47. doi: 10.1016/j.bbmt.2005.03.003. Biol Blood Marrow Transplant. 2005. PMID: 15931632 Free article.
292 results